BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
BioCentury | Nov 1, 2019
Product Development

Novartis, Merck KGaA see opportunity in select pockets of MS patients

As companies continue to pile into the multiple sclerosis market with new therapies, Novartis and Merck KGaA are dissecting the landscape to define populations for their newly launched drugs. While the former is staking out...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BioCentury | Aug 10, 2019
Regulation

Timeline of a debacle: Novartis missteps hold lessons for diligence, new modalities

Aside from all the questions about who knew what when, and how they should have acted, the Zolgensma data fiasco reveals that Novartis’ due diligence team missed some warning signs. The case has the hallmarks...
BC Extra | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
Items per page:
1 - 10 of 3583
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BC Innovations | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
BioCentury | Nov 1, 2019
Product Development

Novartis, Merck KGaA see opportunity in select pockets of MS patients

As companies continue to pile into the multiple sclerosis market with new therapies, Novartis and Merck KGaA are dissecting the landscape to define populations for their newly launched drugs. While the former is staking out...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BioCentury | Aug 10, 2019
Regulation

Timeline of a debacle: Novartis missteps hold lessons for diligence, new modalities

Aside from all the questions about who knew what when, and how they should have acted, the Zolgensma data fiasco reveals that Novartis’ due diligence team missed some warning signs. The case has the hallmarks...
BC Extra | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

As it gears up to enter the clinic next quarter, neurodegeneration company Yumanity hired Richard Peters as CEO to succeed Tony Coles, aiming to leverage Peters’ experience managing neurology trials into at least three clinical...
Items per page:
1 - 10 of 3583